Journal Article
. 2009 Jul; 23(4):244-8.
doi: 10.1002/jcla.20323.

Cancer antigen 125 levels in inflammatory bowel diseases

Hilmi Ataseven 1 Zeynel Abidin Oztürk  Mehmet Arhan  Osman Yüksel  Seyfettin Köklü  Mehmet Ibiş  Omer Başar  Fatma Meriç Yilmaz  Ilhami Yüksel  
  • PMID: 19623645
  •     31 References
  •     5 citations


Background: Cancer antigen 125 (CA-125) is a tumor marker used for the diagnosis and monitoring of ovarian carcinoma. It can also be elevated in endometriosis, inflammations, and in nongynecological malignancies. Up to date, serum CA-125 levels in inflammatory bowel diseases (IBD) have not been studied before.

Aim: To assess the levels of CA-125 in patients with ulcerative colitis (UC) and Crohn's disease (CD).

Methods: Serum levels of CA-125 were investigated in 68 cases with UC (male/female: 47/21), 32 CD (male/female: 21/11), and 31 healthy controls (male/female: 16/15). Levels of CA-125 were also compared among UC patients according to lesion location, severity, and activity of CD.

Results: Serum CA-125 levels were 17.29+/-24.50 U/ml, 15.56+/-20.74 U/ml, and 8.85+/-2.62 U/ml in patients with UC, CD, and healthy controls, respectively. Serum CA-125 levels were significantly higher in UC compared to control group (P=0.001). Serum CA-125 levels were higher in CD patients compared to control group but there was no significance (P=0.087). Serum CA-125 levels were higher in pancolitis compared to distal type and left-sided UC.

Conclusions: Our data suggest that serum CA-125 levels may be increased in patients with IBDs.

Immune dysfunction in inflammatory bowel disease.
Manuela G Neuman.
Transl Res, 2007 Mar 27; 149(4). PMID: 17383591
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.
W R Best, J M Becktel, J W Singleton, F Kern.
Gastroenterology, 1976 Mar 11; 70(3). PMID: 1248701
Highly Cited.
Current and future diagnostic approaches: from serologies to imaging.
David H Bruining, Edward V Loftus.
Curr Gastroenterol Rep, 2008 Apr 02; 9(6). PMID: 18377802
Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease.
A G Røseth, E Aadland, K Grzyb.
Scand J Gastroenterol, 2004 Oct 30; 39(10). PMID: 15513345
New concepts in the pathophysiology of inflammatory bowel disease.
Giorgos Bamias, Mark R Nyce, +3 authors, American Physiological Society.
Ann Intern Med, 2005 Dec 21; 143(12). PMID: 16365470
Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis.
A Bitton, M A Peppercorn, +8 authors, A C Stevens.
Gastroenterology, 2001 Feb 24; 120(1). PMID: 11208709
Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation.
Sunanda V Kane, William J Sandborn, +5 authors, Stephen B Hanauer.
Am J Gastroenterol, 2003 Jun 24; 98(6). PMID: 12818275
Utility of a rapid fecal latex agglutination test detecting the neutrophil protein, lactoferrin, for diagnosing inflammatory causes of chronic diarrhea.
K D Fine, F Ogunji, +2 authors, R L Guerrant.
Am J Gastroenterol, 1998 Aug 26; 93(8). PMID: 9707055
Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease.
Craig A Solem, Edward V Loftus, +3 authors, William J Sandborn.
Inflamm Bowel Dis, 2005 Jul 27; 11(8). PMID: 16043984
Highly Cited.
Review article: Crohn's disease: monitoring disease activity.
R Sostegni, M Daperno, +3 authors, A Pera.
Aliment Pharmacol Ther, 2003 Jun 06; 17 Suppl 2. PMID: 12786607
Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease.
I E Koutroubakis, E Petinaki, +5 authors, E A Kouroumalis.
Am J Gastroenterol, 2001 Mar 10; 96(2). PMID: 11232689
Laboratory markers in IBD: useful, magic, or unnecessary toys?
S Vermeire, G Van Assche, P Rutgeerts.
Gut, 2006 Feb 14; 55(3). PMID: 16474109    Free PMC article.
Highly Cited. Review.
Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease.
M Peeters, S Joossens, +3 authors, P Rutgeerts.
Am J Gastroenterol, 2001 Mar 31; 96(3). PMID: 11280542
Cancer antigen 125 associated with multiple benign and malignant pathologies.
C Miralles, M Orea, +7 authors, T Gea.
Ann Surg Oncol, 2003 Mar 07; 10(2). PMID: 12620910
Network of inflammatory cytokines and correlation with disease activity in ulcerative colitis.
R Guimbaud, V Bertrand, +5 authors, S Chaussade.
Am J Gastroenterol, 1998 Dec 22; 93(12). PMID: 9860399
CA125 production by the peritoneum: in-vitro and in-vivo studies.
M Epiney, C Bertossa, +2 authors, P Bischof.
Hum Reprod, 2000 Jun 01; 15(6). PMID: 10831552
Molecular pathogenesis of inflammatory bowel disease: genotypes, phenotypes and personalized medicine.
Philippe Goyette, Catherine Labbé, +2 authors, John D Rioux.
Ann Med, 2007 Apr 26; 39(3). PMID: 17457716
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.
R C Bast, T L Klug, +9 authors, R C Knapp.
N Engl J Med, 1983 Oct 13; 309(15). PMID: 6310399
Highly Cited.
Serum carbohydrate antigen 125 levels in advanced heart failure: relation to B-type natriuretic peptide and left atrial volume.
Dursun Duman, Fatih Palit, Ergun Simsek, Karadag Bilgehan.
Eur J Heart Fail, 2008 May 27; 10(6). PMID: 18501671
Cancer antigen 125 and prognosis.
Estrid Høgdall.
Curr Opin Obstet Gynecol, 2008 Jan 17; 20(1). PMID: 18196998
Cortisone in ulcerative colitis; final report on a therapeutic trial.
Br Med J, 1955 Oct 29; 2(4947). PMID: 13260656    Free PMC article.
Highly Cited.
Recent understanding of IBD pathogenesis: implications for future therapies.
Torsten Kucharzik, Christian Maaser, +4 authors, Wolfram Domschke.
Inflamm Bowel Dis, 2006 Nov 01; 12(11). PMID: 17075348
CA 125 secretion by peritoneal mesothelial cells.
A M Zeillemaker, H A Verbrugh, A A Hoynck van Papendrecht, P Leguit.
J Clin Pathol, 1994 Mar 01; 47(3). PMID: 8163699    Free PMC article.
Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease.
W J Sandborn, E V Loftus, +11 authors, S R Targan.
Inflamm Bowel Dis, 2001 Aug 23; 7(3). PMID: 11515844
Review of fecal biomarkers in inflammatory bowel disease.
Andrew D Sutherland, Richard B Gearry, Frank A Frizelle.
Dis Colon Rectum, 2008 Jun 11; 51(8). PMID: 18543035
New players in the cytokine orchestra of inflammatory bowel disease.
Massimo C Fantini, Giovanni Monteleone, Thomas T Macdonald.
Inflamm Bowel Dis, 2007 Aug 23; 13(11). PMID: 17712836
The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters.
Nikos T Kouris, Ioannis D Zacharos, +5 authors, Dimitris K Babalis.
Eur J Heart Fail, 2005 Feb 11; 7(2). PMID: 15701467
Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
D Rachmilewitz.
BMJ, 1989 Jan 14; 298(6666). PMID: 2563951    Free PMC article.
Highly Cited.
CA125: megadaltons of novel opportunities.
Oliver Dorigo, Jonathan S Berek.
Gynecol Oncol, 2007 Feb 20; 104(3). PMID: 17306691
Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Jost Langhorst, Sigrid Elsenbruch, +3 authors, Gustav J Dobos.
Am J Gastroenterol, 2007 Oct 06; 103(1). PMID: 17916108
Highly Cited.
Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis.
C G B Peterson, P Sangfelt, +3 authors, M Carlson.
Scand J Clin Lab Invest, 2007 Nov 24; 67(8). PMID: 18034391
Correlates of the preoperative level of CA125 at presentation of ovarian cancer.
Daniel W Cramer, Allison F Vitonis, +4 authors, Ross S Berkowitz.
Gynecol Oncol, 2010 Sep 21; 119(3). PMID: 20850174    Free PMC article.
Clinical laboratory and imaging evidence for effectiveness of agarose-agarose macrobeads containing stem-like cells derived from a mouse renal adenocarcinoma cell population (RMBs) in treatment-resistant, advanced metastatic colorectal cancer: Evaluation of a biological-systems approach to cancer therapy (U.S. FDA IND-BB 10091; NCT 02046174, NCT 01053013).
Barry H Smith, Lawrence S Gazda, +11 authors, David J Wolf.
Chin J Cancer Res, 2018 Mar 17; 30(1). PMID: 29545721    Free PMC article.
Chronic Medical Conditions and CA125 Levels among Women without Ovarian Cancer.
Babatunde O Akinwunmi, Ana Babic, +4 authors, Kathryn L Terry.
Cancer Epidemiol Biomarkers Prev, 2018 Sep 22; 27(12). PMID: 30237250    Free PMC article.
Development and validation a simple model for identify malignant ascites.
Ying-Yun Guo, Xiu-Lan Peng, +3 authors, Wei-Guo Dong.
Int J Med Sci, 2021 Apr 15; 18(9). PMID: 33850466    Free PMC article.
Early Postnatal Comprehensive Biomarkers Cannot Identify Extremely Preterm Infants at Risk of Developing Necrotizing Enterocolitis.
Alice Hoffsten, Laszlo Markasz, +2 authors, Richard Sindelar.
Front Pediatr, 2021 Nov 09; 9. PMID: 34746064    Free PMC article.